AnaptysBio, Inc.
ANAB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $375,778 | $576,712 | $872,833 | $953,227 |
| - Cash | $123,080 | $35,965 | $71,308 | $495,729 |
| + Debt | $369,463 | $17,814 | $19,450 | $20,955 |
| Enterprise Value | $622,161 | $558,561 | $820,975 | $478,453 |
| Revenue | $91,280 | $17,157 | $10,287 | $63,175 |
| % Growth | 432% | 66.8% | -83.7% | – |
| Gross Profit | -$72,560 | -$115,126 | -$78,511 | -$35,321 |
| % Margin | -79.5% | -671% | -763.2% | -55.9% |
| EBITDA | -$92,744 | -$156,420 | -$105,257 | -$55,706 |
| % Margin | -101.6% | -911.7% | -1,023.2% | -88.2% |
| Net Income | -$145,231 | -$163,619 | -$128,724 | -$57,796 |
| % Margin | -159.1% | -953.7% | -1,251.3% | -91.5% |
| EPS Diluted | -5.12 | -6.08 | -4.57 | -2.11 |
| % Growth | 15.8% | -33% | -116.6% | – |
| Operating Cash Flow | -$135,337 | -$120,800 | -$73,593 | -$45,920 |
| Capital Expenditures | -$358 | -$807 | -$358 | -$1,366 |
| Free Cash Flow | -$135,695 | -$121,607 | -$73,951 | -$47,286 |